Bluejay's filing says a release covered baseline patient details from its SYMON-II study. It gives no study findings or business changes, so it does not change the company's outlook.
Baseline patient details describe who joined a study, not whether its test worked. The filing gives no test-performance results or other business changes, so it does not shift the outlook.
Follow Bluejay Diagnostics, Inc. (BJDX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BJDX